See more : Small Business Development Group, Inc. (SBDG) Income Statement Analysis – Financial Results
Complete financial analysis of SynBiotic SE (SBX.DE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SynBiotic SE, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- KJMC Corporate Advisors (India) Limited (KJMCCORP.BO) Income Statement Analysis – Financial Results
- Viemed Healthcare, Inc. (VMD.TO) Income Statement Analysis – Financial Results
- Shanghai Electric Group Company Limited (SIELF) Income Statement Analysis – Financial Results
- KATITAS CO., Ltd. (8919.T) Income Statement Analysis – Financial Results
- Ningbo Marine Company Limited (600798.SS) Income Statement Analysis – Financial Results
SynBiotic SE (SBX.DE)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.synbiotic.com
About SynBiotic SE
SynBiotic SE engages in the development of medicines and over-the-counter wellness products based on cannabinoids. It focuses on synthetic production of cannabinoids, drug development, nutritional supplements, and cosmetic products. The company was formerly known as Ledgertech SE and changed its name to Ledgertech SE. SynBiotic SE based in Munich, Germany.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 3.86M | 8.17M | 9.06M | 5.47M | 0.00 | 0.00 |
| Cost of Revenue | 2.35M | 4.59M | 3.86M | 1.73M | 0.00 | 0.00 |
| Gross Profit | 1.51M | 3.57M | 5.20M | 3.74M | 0.00 | 0.00 |
| Gross Profit Ratio | 39.01% | 43.75% | 57.38% | 68.33% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 880.91K | 1.08M | 1.48M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 524.62K | 1.59M | 2.30M | 0.00 | 0.00 | 0.00 |
| SG&A | 1.41M | 2.68M | 7.62M | 3.61M | 13.43K | 0.00 |
| Other Expenses | 213.81K | 510.80K | 16.64M | 4.46M | 13.43K | 822.00 |
| Operating Expenses | 1.51M | 28.98M | 16.64M | 4.46M | 13.43K | 822.00 |
| Cost & Expenses | 11.44M | 33.57M | 20.50M | 6.19M | 13.43K | 822.00 |
| Interest Income | 81.75K | 151.79K | 133.58K | 20.23K | 0.00 | 0.00 |
| Interest Expense | 195.24K | 188.90K | 46.64K | 22.87K | 0.00 | 0.00 |
| Depreciation & Amortization | 4.55M | 1.60M | 744.58K | 119.80K | 13.43K | 161.14K |
| EBITDA | -7.12M | -24.17M | -10.62M | -716.12K | -1.00 | -822.00 |
| EBITDA Ratio | -184.46% | -74.76% | -54.49% | -11.02% | 0.00% | 0.00% |
| Operating Income | -7.58M | -24.62M | -13.25M | -722.71K | -13.43K | -822.00 |
| Operating Income Ratio | -196.35% | -301.47% | -146.23% | -13.21% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.29M | -23.38M | -1.86M | -138.09K | 0.00 | 0.00 |
| Income Before Tax | -11.87M | -26.19M | -13.36M | -858.80K | -13.43K | -822.00 |
| Income Before Tax Ratio | -307.44% | -320.69% | -147.39% | -15.69% | 0.00% | 0.00% |
| Income Tax Expense | -134.91K | -188.81K | -289.71K | 21.59K | -13.43K | -161.14K |
| Net Income | -10.63M | -24.36M | -13.07M | -880.39K | -13.43K | -822.00 |
| Net Income Ratio | -275.31% | -298.35% | -144.20% | -16.09% | 0.00% | 0.00% |
| EPS | -2.24 | -5.90 | -4.21 | -0.55 | -0.05 | 0.00 |
| EPS Diluted | -2.24 | -5.90 | -4.21 | -0.55 | -0.05 | 0.00 |
| Weighted Avg Shares Out | 4.75M | 4.13M | 3.10M | 1.59M | 260.07K | 1.56M |
| Weighted Avg Shares Out (Dil) | 4.75M | 4.13M | 3.10M | 1.59M | 260.07K | 1.56M |
Source: https://incomestatements.info
Category: Stock Reports